Joseph Stringer
Stock Analyst at Needham
(4.13)
# 458
Out of 5,241 analysts
323
Total ratings
47.9%
Success rate
14.55%
Average return
Main Sectors:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Downgrades: Hold | n/a | $41.03 | - | 22 | Mar 31, 2026 | |
| BIOA BioAge Labs | Initiates: Buy | $50 | $18.72 | +167.17% | 1 | Mar 27, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $103 → $105 | $75.68 | +38.74% | 27 | Mar 25, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $35 → $40 | $31.36 | +27.55% | 25 | Mar 17, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $139 → $130 | $93.63 | +38.84% | 31 | Mar 17, 2026 | |
| VIR Vir Biotechnology | Maintains: Buy | $14 → $18 | $9.09 | +98.02% | 20 | Feb 24, 2026 | |
| GILD Gilead Sciences | Reiterates: Buy | $170 | $132.06 | +28.73% | 11 | Feb 23, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $529 → $510 | $293.45 | +73.79% | 25 | Feb 12, 2026 | |
| PCVX Vaxcyte | Maintains: Buy | $90 → $110 | $53.52 | +105.55% | 18 | Jan 7, 2026 | |
| RNA Atrium Therapeutics | Downgrades: Hold | $65 | $13.27 | +389.83% | 19 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $50.03 | - | 9 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 | $13.05 | +114.56% | 52 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $11 | $5.37 | +104.84% | 19 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $450.41 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $2.33 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.17 | +758.37% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $22.09 | +67.50% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $16.51 | +9.02% | 2 | Aug 24, 2021 |
Apellis Pharmaceuticals
Mar 31, 2026
Downgrades: Hold
Price Target: n/a
Current: $41.03
Upside: -
BioAge Labs
Mar 27, 2026
Initiates: Buy
Price Target: $50
Current: $18.72
Upside: +167.17%
Ionis Pharmaceuticals
Mar 25, 2026
Maintains: Buy
Price Target: $103 → $105
Current: $75.68
Upside: +38.74%
Stoke Therapeutics
Mar 17, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $31.36
Upside: +27.55%
Rhythm Pharmaceuticals
Mar 17, 2026
Maintains: Buy
Price Target: $139 → $130
Current: $93.63
Upside: +38.84%
Vir Biotechnology
Feb 24, 2026
Maintains: Buy
Price Target: $14 → $18
Current: $9.09
Upside: +98.02%
Gilead Sciences
Feb 23, 2026
Reiterates: Buy
Price Target: $170
Current: $132.06
Upside: +28.73%
Alnylam Pharmaceuticals
Feb 12, 2026
Maintains: Buy
Price Target: $529 → $510
Current: $293.45
Upside: +73.79%
Vaxcyte
Jan 7, 2026
Maintains: Buy
Price Target: $90 → $110
Current: $53.52
Upside: +105.55%
Atrium Therapeutics
Oct 27, 2025
Downgrades: Hold
Price Target: $65
Current: $13.27
Upside: +389.83%
Oct 20, 2025
Reiterates: Hold
Price Target: n/a
Current: $50.03
Upside: -
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $13.05
Upside: +114.56%
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $5.37
Upside: +104.84%
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $450.41
Upside: -
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $2.33
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.17
Upside: +758.37%
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $22.09
Upside: +67.50%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $16.51
Upside: +9.02%